Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
warts
MeSH D014860 - warts
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D014412:
Tumor virus infections
0 Companies
0 Drugs
Success rate
D017193:
Viral skin diseases
0 Companies
0 Drugs
Success rate
D030361:
Papillomavirus infections
2 Companies
0 Drugs
Success rate
D014860:
Warts
9 Companies
8 Drugs
$
Success rate
D003218:
Condylomata acuminata
12 Companies
2 Drugs
$
Success rate
D004819:
Epidermodysplasia verruciformis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Verrica Pharmaceuticals
Cantharidin
Ycanth
2035-05-28
2023-07-21
Clinical Trials
Historical Success Rate
Phase 1
50
%
1/2
Phase 2
17
%
2/12
Phase 3
70
%
7/10
Approved:
7
Overall Success rate:
6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Merck Sharp & Dohme
Ribavirin
,
Interferon alfa-2b
,
Peginterferon alfa-2b
,
Sodium chloride
Roche
Interferon alfa-2a
,
Peginterferon alfa-2a
,
Ribavirin
Verrica Pharmaceuticals
Cantharidin
,
Salicylic acid
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use